# Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse

> **NCT00677716** · PHASE2 · COMPLETED · sponsor: **Peregrine Pharmaceuticals** · enrollment: 41 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** 131I-chTNT-1/B MAb (Cotara)

## Key facts

- **NCT ID:** NCT00677716
- **Lead sponsor:** Peregrine Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2011-09
- **Final completion:** 2011-11
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2014-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00677716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00677716, "Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00677716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*